Search research articles
Contact Us
Filters
Showing results (51-60 of 79) with videos related to
Page
of 8
Sort By:
The Journal of Antimicrobial Chemotherapy
|
October 8, 2024
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease
Ralf Stemkens, Arthur Lemson, Simon E Koele, et al.
Transplantation Reviews (Orlando, Fla.)
|
October 13, 2023
Non-tuberculous mycobacteria disease pre-lung transplantation: A systematic review of the treatment regimens and duration pre- and post-transplant
Johanna P van Gemert, Sofanne J Ravensbergen, Erik A M Verschuuren, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
July 31, 2021
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
Mike Marvin Ruth, Jelmer Raaijmakers, Erik van den Hombergh, et al.
Chest
|
August 15, 2021
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
Rabi Danho, Jodie A Schildkraut, Sanne M H Zweijpfenning, et al.
The European Respiratory Journal
|
April 9, 2019
Nontuberculous mycobacterial pulmonary disease and <i>Aspergillus</i> co-infection: Bonnie and Clyde?
Kim Geurts, Sanne M H Zweijpfenning, Lian J Pennings, et al.
Antimicrobial Agents and Chemotherapy
|
January 23, 2024
Clofazimine as a substitute for rifampicin improves efficacy of <i>Mycobacterium avium</i> pulmonary disease treatment in the hollow-fiber model
Sandra Salillas, Jelmer Raaijmakers, Rob E Aarnoutse, et al.
Antimicrobial Agents and Chemotherapy
|
July 3, 2019
Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in <i>Mycobacterium abscessus</i>
Mike Marvin Ruth, Mara van Rossum, Valerie A C M Koeken, et al.
Med (New York, N.Y.)
|
August 30, 2022
Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series
Cynthia van Arkel, Martin Boeree, Cécile Magis-Escurra, et al.
The European Respiratory Journal
|
November 3, 2018
Clofazimine does not lead to significant QT interval prolongation: a multicentre study
Sanne M H Zweijpfenning, Hester van Groningen, Jakko van Ingen, et al.
Plos One
|
March 18, 2021
Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study
Niels Pouw, Josephine van de Maat, Karin Veerman, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 79) with videos related to
Sort By:
Page
of 8
The Journal of Antimicrobial Chemotherapy
|
October 8, 2024
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease
Ralf Stemkens, Arthur Lemson, Simon E Koele, et al.
Transplantation Reviews (Orlando, Fla.)
|
October 13, 2023
Non-tuberculous mycobacteria disease pre-lung transplantation: A systematic review of the treatment regimens and duration pre- and post-transplant
Johanna P van Gemert, Sofanne J Ravensbergen, Erik A M Verschuuren, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
July 31, 2021
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
Mike Marvin Ruth, Jelmer Raaijmakers, Erik van den Hombergh, et al.
Chest
|
August 15, 2021
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
Rabi Danho, Jodie A Schildkraut, Sanne M H Zweijpfenning, et al.
The European Respiratory Journal
|
April 9, 2019
Nontuberculous mycobacterial pulmonary disease and <i>Aspergillus</i> co-infection: Bonnie and Clyde?
Kim Geurts, Sanne M H Zweijpfenning, Lian J Pennings, et al.
Antimicrobial Agents and Chemotherapy
|
January 23, 2024
Clofazimine as a substitute for rifampicin improves efficacy of <i>Mycobacterium avium</i> pulmonary disease treatment in the hollow-fiber model
Sandra Salillas, Jelmer Raaijmakers, Rob E Aarnoutse, et al.
Antimicrobial Agents and Chemotherapy
|
July 3, 2019
Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in <i>Mycobacterium abscessus</i>
Mike Marvin Ruth, Mara van Rossum, Valerie A C M Koeken, et al.
Med (New York, N.Y.)
|
August 30, 2022
Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series
Cynthia van Arkel, Martin Boeree, Cécile Magis-Escurra, et al.
The European Respiratory Journal
|
November 3, 2018
Clofazimine does not lead to significant QT interval prolongation: a multicentre study
Sanne M H Zweijpfenning, Hester van Groningen, Jakko van Ingen, et al.
Plos One
|
March 18, 2021
Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study
Niels Pouw, Josephine van de Maat, Karin Veerman, et al.
Page
of 8